Clinical trial
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
NCT00136396 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00136396 |
|---|---|
| Title | Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease |
| Official title | An Open Label, Phase I/II Trial of Rituximab Therapy for Steroid-Refractory Chronic Graft vs. Host Disease |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 30 |
| Start date | Jan 1, 2004 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2010 |
| First posted | Aug 29, 2005 |
| Last update posted | Jun 12, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: